1. Scripps Research Institute Scientists Identify First Potentially Effective Therapy for Human Prion Disease   
  2. Probe from SRIMSC Enters Phase II/III Clinical trials.   
  3. The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!   
  4. Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science   
  5. NIH Common Fund researchers uncover structure of important target for drug design   
  6. NIH Research Matters: Designing New Diabetes Drugs   
  7. Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]    
  8. Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand   
  9. Scripps Research and MIT scientists discover class of potent anti-cancer compounds    
  10. MLP Probe Project Leads to First in Human Studies    
  11. Business Wire:   Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis   
  12. Nature:   Quantitative reactivity profiling predicts functional cysteines in proteomes.

  13. Nature:   Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5.
  14. Discovery and optimization of chemical probes to define important molecular signals in medicine.
  15. Nature Reviews Drug Discovery article:   Chemical modulators of S1P receptors as barrier-oriented therapeutic molecules.
  16. Nature Chemical Biology article: S1P1 signaling just keeps going and going and going…
  17. Nature Biotechnology article:   Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.
Home
Welcome

The Scripps Research Institute has been awarded more than $80 million by the National Institutes of Health to greatly expand the work of The Scripps Research Molecular Screening Center, further strengthening the collaborative efforts of teams of scientists at the La Jolla, California and Jupiter, Florida campuses. The six-year grant is the largest ever awarded to Scripps Research.

The Scripps Research Institute Molecular Screening Center will use Scripps Florida's high throughput robotics to screen discoveries made in laboratories in La Jolla and Jupiter, as well as other research institutions, against various biological targets. The goal is to uncover "proof-of-concept molecules" that could be useful in developing new treatments for a large number of human diseases.

The Scripps center is one of only four such large centers nationwide. Together with five smaller specialized centers, they comprise the Molecular Libraries Production Centers Network, a part of the NIH's strategic funding plan, the Roadmap Initiative.

To read further, click on the following icons;      

 
Center Description

The goal of the MLPCN is to integrate high-throughput chemical approaches with state-of-the art genetics (cellular, molecular and in vivo biology in a multi-disciplinary effort to discover of proof-of-concept (POC) molecular probes for cell and in vivo systems. Probes help transform biomedical advances to impact on public health and quality of life.

Read more...
 
What can the MLPCN Center do for you?

We offer researchers access to our large scale high throughput screening capacity, the type of which was only previously available in the industrial sector. Access is made available to the still-growing Molecular Libraries Small Molecule Repsitory (MLSMR) compound collection of over 317,000 molecules, which includes diversity compounds, DEA controlled substances, natural products, a GPCR targeted library, an ion channel targeted library and many more.

Our staff are experts in the areas of assay optimization, high throughput screening, chemistry, informatics and dmpk, many with pharmaceutical and biotech experience. We work closely with assay providers and provide consulation and support for grant applications, assay optimization and miniturization, pilot screening data, probe synthesis and much more!

Probes help transform biomedical advances to impact on public health and quality of life. We welcome your interest.
 
Accessing our expertise and facilities

Please refer to our contact information page.

 
Copyright (c) 2008-2011 TSRI.